Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus docetaxel in driver-mutation-negative lung adenocarcinoma
ChiCTR1800018500Phase 4Not yet recruiting
- Sponsor
- People's Hospital of Tongliang District, Chongqing
- Start
- Oct 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and docetaxel in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by People's Hospital of Tongliang District, Chongqing. Primary endpoint: progression-free survival. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
Rivoceranibdocetaxel
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800018500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018500.